Новые перспективы персонифицированной терапии хронического вирусного гепатита с



Цитировать

Полный текст

Аннотация

Цель данного обзора - проанализировать возможности традиционной терапии и новые открывающиеся перспективы и подходы к персонифицированной терапии пациентов с хроническим вирусным гепатитом С. Рассмотрены факторы вируса и пациента, которые оказывают влияние на эффективность терапии интерфероном-а 2 и рибави-рином. Представлены данные о молекулярном механизме действия этих лекарственных препаратов. Рассмотрены новые антивирусные препараты (ингибитор протеазы) и фармакологические вещества, находящиеся в разработке и направленные на полимеразу вируса и белок NS5A.

Полный текст

Новые перспективы персонифицированной терапии хронического вирусного гепатита с
×

Об авторах

Георгий Витальевич Сапронов

ГБОУ ДПО «Российская медицинская академия последипломного образования»

Email: geo8@inbox.ru
доцент каф. инфекционных болезней, канд. мед. наук 123995, Москва, ул. Баррикадная, 2

Людмила Ивановна Николаева

ФГБУ «НИИ вирусологии им. Д.И. Ивановского» Минздрава России

Email: L.i.nikolaeva@mail.ru
123098, Москва, ул. Гамалеи, 16

Список литературы

  1. Гайдаренко А.Д. Прогнозирование проявлений эпидемиологического процесса гепатита С на основе компьютерного моделирования. Автореф. дис.. канд. биол. наук. М.; 2009.
  2. Robbins P.S., Myers G., Howard C. et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on virus taxonomy. Arch. Virol. 1998; 143: 24932503.
  3. Choo Q.-L., Kuo G., Wiener A.L. et al. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
  4. Yu X, Qiao M, Atanasov I. et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology. 2007; 367: 126-34.
  5. Nielsen S.U., Bassendine M.F., Martin C. et al. Characterization of hepatitis C RNA-containing particles from human liver by density and size. J. Gen. Virol. 2008; 89: 2507-17.
  6. Gastaminza P., Dryden K.A., Boyd B. et al. Ultrastructural and biophysical characterization of hepatitis C virus particles, pro duced in cell culture. J. Virol. 2010; 84: 10999-11009.
  7. Simmonds P., Bukh J., Combet C. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. J. Hepatol. 2005; 42: 962-73.
  8. Бурневич Э. Уроки IDEAL. Врач. 2008; Специальный выпуск: 1-20.
  9. Nelson D.R., Davis G.L., Jacobson I. et al. Вирусный гепатит С: критическая оценка подходов к лечению. Клиническая гастроэнтерология и гепатология (русское изд.). 2009; 2: 33957.
  10. Poynard T., McHutchison, Goodman Z. et al. (for the ALGOVIRC Project Group). Is an «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000; 31: 211-18.
  11. Соринсон С.Н. В кн.: Вирусные гепатиты. СПб.: Теза; 1998: 201
  12. Chevaliez S., Pawlotsky J.M. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 2007; 59: 1222-41.
  13. Huang Z., Murray M.G., Secrist J.A. Recent development of therapeutics for chronic HCV infection. Antiviral res. 2006; 71: 351-62.
  14. Pawlotsky J.M., Dahari H., Neumann A.U. et al. Antiviral action of ribavirin in chronic hepatirtis C. Gastroenterology. 2004; 126: 703 14.
  15. Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peginter-feron with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009; 360: 1839-50.
  16. Hofmann W.P., Herrmann E., Sarrazin C. et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008; 28: 1332-43.
  17. Gish R.G., Arora S., Rajender Reddy K. et al. Virilogical response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegy-lated interferon alfa-2a: randomized, phase 2 study. J. Hepatology. 2007; 47: 51-9.
  18. Hadziyanns S.J., Sette H. Jr., Morgan T.R. et al. Peginterferon-al-pha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-55.
  19. Roulot D., Bourcier V., Grando V. et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J. Viral. Hepatol. 2007; 14: 460-7.
  20. Enomoto N., Sakuma I., Asahira Y. et al. Comparision of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 1995; 96: 224-30.
  21. Brillet R., Penin F., Hezode C. et al. The nonstructural 5A protein of hepatitis c virus genotype 1b does not contain an interferon sensitiv-ity-determination region. J. Infect. Dis. 2007; 195: 432-41.
  22. Yuan H.J., Jain M., Snow K.K. et al. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribabirin therapy. J. Viral. Hepatol. 2010; 17: 208-16.
  23. Jardim A.C., Yamasaki L.H., de Queiróz A.T. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin. Infect. Genet. Evol. 2009; 9: 689-98.
  24. Munoz de Rueda P., Casado J., Paton R. et al. Mutation in E2-PeRHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferonribavirin therapy responses. J. Virol. 2008; 82: 6644-53.
  25. Akuta N., Suzuki F., Sezaki H. et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005; 48: 372-80.
  26. Akuta N., Suzuki F., Hirakawa M. et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained viro-logical response. J. Med. Virol. 2009; 81: 452-8.
  27. Alestig E., Arnholm B., Eilard A. et al. Core mutations, IL-28B poly-morfisms and respose to peginterferon/ribavirin treatment in Swedish patients infected with hepatitis C virus genotype 1 infection. BMC Infect. Dis. 2011; 11: 124-30.
  28. Taylor D.R., Shi S.T., Romano PR. et al. Inhibition of the interferon-inducible protein kinase PRK by HCV E2 protein. Science. 1999; 285: 107-10.
  29. Boicic F., Sede M., Moretti F et al. Ananlysis of the PKR-eIF2alpha phosphorilation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch. Virol. 2012; 157: 703-11.
  30. Noguchi T., Otsubaki T., Ando I. et al. Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome. Virology. 2008; 375: 424-32.
  31. Chevalies S., Asselah T. Mechanism of non-response to antiviral treatment in chronic hepatitis C. Clin. Res. Hepatol. Gastroenterol. 2011; 55: S31-41.
  32. Николаева Л.И., Макашова В.В., Петрова Е.В. и др. Снижение содержания антител к вирусу гепатита С при антивирусной терапии. Биомедицинская химия. 2009; 55: 201-12.
  33. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
  34. Suppiah V, Moldovan M., Ahlensiel G. et al. IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genet. 2009; 41: 1100-4.
  35. Tanaka Y., Nishida N., Sugiyama M. et al. Genome-wide association with response to pegylated inetrferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.
  36. Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL-28B and spontanepus clearance of hepatitis C virus. Nature. 2009; 461: 798-801.
  37. Sarasin-Filipowics M., Oakeley E.J., Duong FH. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Prec. Natl. Asad. Sci (USA). 2008; 105: 7034-9.
  38. Asselah T., Bieche I., Bedossa P. et al. Gene expression and hepatitis C virus infection. Gut. 2009; 58: 846-58.
  39. McGilvray I., Feld J.J., Chen L. et al. Hepatic cell-specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012; 142: 1122-31.
  40. Butera D., Marukian S., Iwamaye A.E. et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005; 106: 1175-82.
  41. Ji X., Cheung R., Cooper S. et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003; 37: 610-21.
  42. Casrouge A., Decalf J., Ahloulay M. et al. Evidance for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 2011; 121: 308-17.
  43. Lagging M., Askarieh G., Negro F et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE. 2011; 6: e17232.
  44. Hinrichsen H., Benhamou Y., Wedemeyer H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol. 2004; 127: 1347-55.
  45. Pawlotsky J.M. The results of phase III clinical trial with telaprevir and boceprevir presented at The Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology. 2011; 140: 746-54.
  46. Silva M., Kasserra C., Gupta S. et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol. Int. 2011; 5: 355-8.
  47. Sanchez-Tapias J.M. Treatment of HCV genotype 1 naive patients with triple therapy: who, when and how long. Giner P., Forns X., Abraldes J.G., eds. In: Therapy liver diseases. Barcelona: Elsevier Doyma; 2011: 23-2.
  48. KwoP.Y., VinayekR. The therapeutic approaches for hepatitis c virus: protease inhibitors and polymerase inhibitors. Gut Liver. 2011; 5: 406-17.
  49. Bartels D.J., Zhou Y., Zhang E.Z. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 2008; 198: 800-7.
  50. Robinson M., Tian Y., Delaney W.E. et al. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Prec. Natl Acad. Sci. (USA). 2011; 108: 10290-5.
  51. Bressanelli S., Tomei L., Roussel A., et al. Crystal structure of RNA-dependent RNA polymerase of hepatitis C virus. Prec. Natl Acad. Sci (USA). 1999; 96: 13034-9.
  52. Guedi J.,Dahari H., Shudo E. et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepa-tology. 2011; 55: 1030-7.
  53. Lalezari J., Gane E., Rodriguez-Torres M. et al. Potent antivaral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days. J. Hepatol. 2008; 48 (Suppl. 2): S29.
  54. Gane E.J., Roberts S.K., Stedman C.A. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010; 376: 1467-75.
  55. Brainard D.M., Anderson M.S., Petry A. et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naive genotype 1a, 1b and 3 HCV-infected patients. Hepatology. 2009; 50 (Suppl. 4): 263A.
  56. Rodriguez-Torres M., Lawitz E., Conway B. et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 treatment-naive genotype 1 HCV-infected patients. J. Hepatol. 2010; 52 (Suppl. 1): S14.
  57. Lawitz E., Rodriguez-Torres M., Rustgi V.K. et al. Safety and antiviral activity of ANA-598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naive genotype 1 chronic HCV patients. J. Hepatol. 2010; 52 (Suppl. 1): S467.
  58. Shih I., Vliegen I., Peng B. et al. Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of HCV NS5B polymerase. Antimicrob. Agents Chemother. 2011; 55: 4196-203.
  59. Gao M., Nettles R.E., Belema M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465: 96-100.
  60. Nettles R., Chien C., Chung E. et al. BMS-790052 is a first-in-class potent hepatitis C (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology. 2008; 48 (Suppl. 1): 1025A.
  61. Lawitz E.J., Gruener D., Hill J.M. et al. A phase 1, randomized, placebo-controlled, three-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol. 2012; 57: 24-31.
  62. Ghany M.G. Nelson D.R., Strader D.B. et al. An update on trea-ment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44.
  63. Casey L.C., Lee W.M. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 2013; 29: 243-9.
  64. Kanda T., Yokosuka D., Omada M. Treatment of hepatitis C virus infection in future. Clinical and Translational Medicine. 2013; 2: www. clintransmed.com/ content/2/1/9.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Эко-вектор", 2013


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014448 от 08.02.1996. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 .


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах